Wednesday, March 17, 2021

Prometheus Biosciences Raises $218.5M In IPO

San Diego-based biotech Prometheus Biosciences has raised $218.5M in its IPO, and is now trading on the Nasdaq as RXDX. The company--which is focused on discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD)--had its IPO underwritten by SVB Leerink,

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.